Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity.

ABSTRACT:

Background

To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.

Methods

Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.

Results

A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC trans

SUBMITTER: Hong J 

PROVIDER: S-EPMC8246035 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature